Storia in 11 fonti

FDA Panel Set To Debate Moderna Flu Shot - Moderna (NASDAQ:MRNA)

Moderna flu vaccine faces a key FDA advisory panel review as analysts weigh approval odds, postmarketing study costs, and growth potential.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

benzinga.com1 mese fa

Moderna's Flu Vaccine Clears Key FDA Panel Vote As Advisory Committee Backs Shot 9-0 - Moderna (NASDAQ:MR

Moderna's mRNA-1010 flu vaccine cleared FDA panel unanimously (9-0) for adults 50+; final approval expected Aug 5, 2026. This signals expansion from COVID-only into multi-respiratory franchise (flu, flu-COVID combo, norovirus), critical for offsetting concentrated revenue exposure.

Leggi questa versione → originale

Timeline cronologica

martedì 16 giugno 2026·biopharmadive.com
FDA staff scrutinizes evidence supporting Moderna’s flu vaccine
Ahead of a Thursday advisory panel meeting, agency scientists highlighted shortcomings in data accrued for a vaccine the FDA controversially refused to even review earlier this…
martedì 16 giugno 2026·medpagetoday.com
FDA Staff Weighs In on Potential First mRNA Flu Shot
Moderna's novel vaccine was at the center of dustup with agency earlier this year

FDA Panel Set To Debate Moderna Flu Shot - Moderna (NASDAQ:MRNA)

Confronto fonti

Moderna's Flu Vaccine Clears Key FDA Panel Vote As Advisory Committee Backs Shot 9-0 - Moderna (NASDAQ:MR

Timeline cronologica

FDA staff scrutinizes evidence supporting Moderna’s flu vaccine

FDA Staff Weighs In on Potential First mRNA Flu Shot

FDA staff scrutinizes evidence supporting Moderna’s flu vaccine

New mRNA flu vaccine faces scrutiny ahead of key FDA decision

FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy

FDA advisors unanimously vote to approve Moderna's mRNA after agency drama

FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

FDA raises efficacy questions for Moderna’s flu vaccine but no dire flags

FDA Panel Set To Debate Moderna Flu Shot - Moderna (NASDAQ:MRNA)

Key FDA committee unanimously recommends its first vaccine since 2023

Moderna flu vaccine wins unanimous support from FDA panel

FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

New mRNA flu vaccine faces scrutiny ahead of key FDA decision

FDA Panel Endorses New Flu Shot That Uses Tech Dissed by RFK Jr.

Bulls Pile Into Moderna As FDA Decision Nears, Ignites 60% Surge In This ETF - Moderna (NASDAQ:MRNA), Def

FDA advisory panel endorses Moderna mRNA flu vaccine that was subject of controversy

FDA panel recommends Moderna’s mRNA flu shot for older adults

FDA advisors unanimously vote to approve Moderna's mRNA after agency drama

New First-of-Its-Kind Flu Vaccine Approved by FDA Expert Panel

Moderna's Flu Vaccine Clears Key FDA Panel Vote As Advisory Committee Backs Shot 9-0 - Moderna (NASDAQ:MR